Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy

Neurotransmitter transporters (NTTs) are involved in the fine-tuning of brain neurotransmitter homeostasis. As such, they are implicated in a plethora of complex behaviors, including reward, movement, and cognition. During recent decades, compounds that modulate NTT functions have been developed. So...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Trends in pharmacological sciences (Regular ed.) 2020-07, Vol.41 (7), p.446-463
Hauptverfasser: Niello, Marco, Gradisch, Ralph, Loland, Claus Juul, Stockner, Thomas, Sitte, Harald H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 463
container_issue 7
container_start_page 446
container_title Trends in pharmacological sciences (Regular ed.)
container_volume 41
creator Niello, Marco
Gradisch, Ralph
Loland, Claus Juul
Stockner, Thomas
Sitte, Harald H.
description Neurotransmitter transporters (NTTs) are involved in the fine-tuning of brain neurotransmitter homeostasis. As such, they are implicated in a plethora of complex behaviors, including reward, movement, and cognition. During recent decades, compounds that modulate NTT functions have been developed. Some of them are in clinical use for the management of different neuropsychiatric conditions. The majority of these compounds have been found to selectively interact with the orthosteric site of NTTs. Recently, diverse allosteric sites have been described in a number of NTTs, modulating their function. A more complex NTT pharmacology may be useful in the development of novel therapeutics. Here, we summarize current knowledge on such modulatory allosteric sites, with specific focus on their pharmacological and therapeutic potential. Current research is showing an increasing heterogeneity in the binding sites available in NTTs. These binding sites are often located distant from the central binding sites, suggesting a higher level of complexity in the regulation of NTT function.Allosteric sites increase specificity, reducing off-target effects.Small molecules can be developed to target NTT allosteric sites, with the possibility to either increase or decrease their functions.NTT allosteric modulators are in advanced clinical trials, emphasizing their potential for the treatment of neuropsychiatric disorders.
doi_str_mv 10.1016/j.tips.2020.04.006
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7610661</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165614720300924</els_id><sourcerecordid>2408206469</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-c8dcb4cf0e217443c7d4017f7662f1f1e33147c01df517f0c58da14a9b2ae0433</originalsourceid><addsrcrecordid>eNp9kVtLJDEQhYO4rLO6f8AH6Udfuq1cOhlBBBFdBS8LOz6HTLp6zNDTaZO04L_fDDOKvgiBFKmvTg51CDmkUFGg8mRZJTfEigGDCkQFIHfIhE4VL7ni9S6ZZKguJRVqj_yKcQkAnDP6k-xxJlTuiQn5e9F1PiYMzhb3vhk7k5zvC98WDzgGn4Lp48qlDBSzdT34kOtYmHyK2TMGM-CY8vC_jCZcvB2QH63pIv7e3vvk6fpqdnlT3j3-ub28uCutqOtU2mlj58K2gIwqIbhVjQCqWiUla2lLkfPs2wJt2jo_g62njaHCnM6ZQRCc75Pzje4wzlfYWOyzgU4Pwa1MeNPeOP2107tnvfCvWkkKUtIscLwVCP5lxJj0ykWLXWd69GPUTMCUgRTyNKNsg9rgYwzYfnxDQa-j0Eu9jkKvo9AgdI4iDx19Nvgx8r77DJxtAMxrenUYdLQOe4uNC2iTbrz7Tv8_2Uuc9A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2408206469</pqid></control><display><type>article</type><title>Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Niello, Marco ; Gradisch, Ralph ; Loland, Claus Juul ; Stockner, Thomas ; Sitte, Harald H.</creator><creatorcontrib>Niello, Marco ; Gradisch, Ralph ; Loland, Claus Juul ; Stockner, Thomas ; Sitte, Harald H.</creatorcontrib><description>Neurotransmitter transporters (NTTs) are involved in the fine-tuning of brain neurotransmitter homeostasis. As such, they are implicated in a plethora of complex behaviors, including reward, movement, and cognition. During recent decades, compounds that modulate NTT functions have been developed. Some of them are in clinical use for the management of different neuropsychiatric conditions. The majority of these compounds have been found to selectively interact with the orthosteric site of NTTs. Recently, diverse allosteric sites have been described in a number of NTTs, modulating their function. A more complex NTT pharmacology may be useful in the development of novel therapeutics. Here, we summarize current knowledge on such modulatory allosteric sites, with specific focus on their pharmacological and therapeutic potential. Current research is showing an increasing heterogeneity in the binding sites available in NTTs. These binding sites are often located distant from the central binding sites, suggesting a higher level of complexity in the regulation of NTT function.Allosteric sites increase specificity, reducing off-target effects.Small molecules can be developed to target NTT allosteric sites, with the possibility to either increase or decrease their functions.NTT allosteric modulators are in advanced clinical trials, emphasizing their potential for the treatment of neuropsychiatric disorders.</description><identifier>ISSN: 0165-6147</identifier><identifier>EISSN: 1873-3735</identifier><identifier>DOI: 10.1016/j.tips.2020.04.006</identifier><identifier>PMID: 32471654</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Allosteric Regulation ; Allosteric Site ; allostery ; competitive and noncompetitive inhibition ; Homeostasis ; Humans ; neurotransmission ; Neurotransmitter Agents ; Neurotransmitter Transport Proteins - drug effects ; therapy ; transporter</subject><ispartof>Trends in pharmacological sciences (Regular ed.), 2020-07, Vol.41 (7), p.446-463</ispartof><rights>2020 The Author(s)</rights><rights>Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-c8dcb4cf0e217443c7d4017f7662f1f1e33147c01df517f0c58da14a9b2ae0433</citedby><cites>FETCH-LOGICAL-c455t-c8dcb4cf0e217443c7d4017f7662f1f1e33147c01df517f0c58da14a9b2ae0433</cites><orcidid>0000-0002-1339-7444</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165614720300924$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32471654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niello, Marco</creatorcontrib><creatorcontrib>Gradisch, Ralph</creatorcontrib><creatorcontrib>Loland, Claus Juul</creatorcontrib><creatorcontrib>Stockner, Thomas</creatorcontrib><creatorcontrib>Sitte, Harald H.</creatorcontrib><title>Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy</title><title>Trends in pharmacological sciences (Regular ed.)</title><addtitle>Trends Pharmacol Sci</addtitle><description>Neurotransmitter transporters (NTTs) are involved in the fine-tuning of brain neurotransmitter homeostasis. As such, they are implicated in a plethora of complex behaviors, including reward, movement, and cognition. During recent decades, compounds that modulate NTT functions have been developed. Some of them are in clinical use for the management of different neuropsychiatric conditions. The majority of these compounds have been found to selectively interact with the orthosteric site of NTTs. Recently, diverse allosteric sites have been described in a number of NTTs, modulating their function. A more complex NTT pharmacology may be useful in the development of novel therapeutics. Here, we summarize current knowledge on such modulatory allosteric sites, with specific focus on their pharmacological and therapeutic potential. Current research is showing an increasing heterogeneity in the binding sites available in NTTs. These binding sites are often located distant from the central binding sites, suggesting a higher level of complexity in the regulation of NTT function.Allosteric sites increase specificity, reducing off-target effects.Small molecules can be developed to target NTT allosteric sites, with the possibility to either increase or decrease their functions.NTT allosteric modulators are in advanced clinical trials, emphasizing their potential for the treatment of neuropsychiatric disorders.</description><subject>Allosteric Regulation</subject><subject>Allosteric Site</subject><subject>allostery</subject><subject>competitive and noncompetitive inhibition</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>neurotransmission</subject><subject>Neurotransmitter Agents</subject><subject>Neurotransmitter Transport Proteins - drug effects</subject><subject>therapy</subject><subject>transporter</subject><issn>0165-6147</issn><issn>1873-3735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kVtLJDEQhYO4rLO6f8AH6Udfuq1cOhlBBBFdBS8LOz6HTLp6zNDTaZO04L_fDDOKvgiBFKmvTg51CDmkUFGg8mRZJTfEigGDCkQFIHfIhE4VL7ni9S6ZZKguJRVqj_yKcQkAnDP6k-xxJlTuiQn5e9F1PiYMzhb3vhk7k5zvC98WDzgGn4Lp48qlDBSzdT34kOtYmHyK2TMGM-CY8vC_jCZcvB2QH63pIv7e3vvk6fpqdnlT3j3-ub28uCutqOtU2mlj58K2gIwqIbhVjQCqWiUla2lLkfPs2wJt2jo_g62njaHCnM6ZQRCc75Pzje4wzlfYWOyzgU4Pwa1MeNPeOP2107tnvfCvWkkKUtIscLwVCP5lxJj0ykWLXWd69GPUTMCUgRTyNKNsg9rgYwzYfnxDQa-j0Eu9jkKvo9AgdI4iDx19Nvgx8r77DJxtAMxrenUYdLQOe4uNC2iTbrz7Tv8_2Uuc9A</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Niello, Marco</creator><creator>Gradisch, Ralph</creator><creator>Loland, Claus Juul</creator><creator>Stockner, Thomas</creator><creator>Sitte, Harald H.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1339-7444</orcidid></search><sort><creationdate>20200701</creationdate><title>Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy</title><author>Niello, Marco ; Gradisch, Ralph ; Loland, Claus Juul ; Stockner, Thomas ; Sitte, Harald H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-c8dcb4cf0e217443c7d4017f7662f1f1e33147c01df517f0c58da14a9b2ae0433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Allosteric Regulation</topic><topic>Allosteric Site</topic><topic>allostery</topic><topic>competitive and noncompetitive inhibition</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>neurotransmission</topic><topic>Neurotransmitter Agents</topic><topic>Neurotransmitter Transport Proteins - drug effects</topic><topic>therapy</topic><topic>transporter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niello, Marco</creatorcontrib><creatorcontrib>Gradisch, Ralph</creatorcontrib><creatorcontrib>Loland, Claus Juul</creatorcontrib><creatorcontrib>Stockner, Thomas</creatorcontrib><creatorcontrib>Sitte, Harald H.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niello, Marco</au><au>Gradisch, Ralph</au><au>Loland, Claus Juul</au><au>Stockner, Thomas</au><au>Sitte, Harald H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy</atitle><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle><addtitle>Trends Pharmacol Sci</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>41</volume><issue>7</issue><spage>446</spage><epage>463</epage><pages>446-463</pages><issn>0165-6147</issn><eissn>1873-3735</eissn><abstract>Neurotransmitter transporters (NTTs) are involved in the fine-tuning of brain neurotransmitter homeostasis. As such, they are implicated in a plethora of complex behaviors, including reward, movement, and cognition. During recent decades, compounds that modulate NTT functions have been developed. Some of them are in clinical use for the management of different neuropsychiatric conditions. The majority of these compounds have been found to selectively interact with the orthosteric site of NTTs. Recently, diverse allosteric sites have been described in a number of NTTs, modulating their function. A more complex NTT pharmacology may be useful in the development of novel therapeutics. Here, we summarize current knowledge on such modulatory allosteric sites, with specific focus on their pharmacological and therapeutic potential. Current research is showing an increasing heterogeneity in the binding sites available in NTTs. These binding sites are often located distant from the central binding sites, suggesting a higher level of complexity in the regulation of NTT function.Allosteric sites increase specificity, reducing off-target effects.Small molecules can be developed to target NTT allosteric sites, with the possibility to either increase or decrease their functions.NTT allosteric modulators are in advanced clinical trials, emphasizing their potential for the treatment of neuropsychiatric disorders.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32471654</pmid><doi>10.1016/j.tips.2020.04.006</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-1339-7444</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0165-6147
ispartof Trends in pharmacological sciences (Regular ed.), 2020-07, Vol.41 (7), p.446-463
issn 0165-6147
1873-3735
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7610661
source MEDLINE; Elsevier ScienceDirect Journals
subjects Allosteric Regulation
Allosteric Site
allostery
competitive and noncompetitive inhibition
Homeostasis
Humans
neurotransmission
Neurotransmitter Agents
Neurotransmitter Transport Proteins - drug effects
therapy
transporter
title Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T08%3A18%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Allosteric%20Modulation%20of%20Neurotransmitter%20Transporters%20as%20a%20Therapeutic%20Strategy&rft.jtitle=Trends%20in%20pharmacological%20sciences%20(Regular%20ed.)&rft.au=Niello,%20Marco&rft.date=2020-07-01&rft.volume=41&rft.issue=7&rft.spage=446&rft.epage=463&rft.pages=446-463&rft.issn=0165-6147&rft.eissn=1873-3735&rft_id=info:doi/10.1016/j.tips.2020.04.006&rft_dat=%3Cproquest_pubme%3E2408206469%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2408206469&rft_id=info:pmid/32471654&rft_els_id=S0165614720300924&rfr_iscdi=true